Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter ...

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...

As part of a U.S. government-wide reduction in force aimed at restructuring and streamlining federal agencies, 5,200 Health ...

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer management. However, acquired resistance and response variability point to rational combination strategies as the goal ...

After withdrawing plans for an IPO last year, Orum Therapeutics Inc. made its debut on the Korea Exchange in 2025 with a ₩50 ...

Stimulating the body’s immune defenses against a tumor can reduce or eliminate it. However, in cancer immunotherapy, when immune checkpoint inhibitors unleash the immune system, severe autoimmunity ...

Researchers from Shanxi Medical University, Nanjing Agricultural University and China Pharmaceutical University, have ...

Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand, GITRL, are involved in immune response ...

Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting ...

In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors ...

Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated ...